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Abstract 6 
Biosensor development requires comprehensive research for establishing the optimal bioassay 7 
conditions that determine the final kinetics, sensitivity and specificity. Different systems have been 8 
developed to study bioreceptor-target interactions but they often have drawbacks, such as long hands-9 
on time, low throughput, high sample consumption and high cost. In this work, the potential of the 10 
novel microfluidic EvalutionTM platform has been evaluated for developing sandwich-based assays in a 11 
fast and high-throughput fashion. An immunoassay for the detection of influenza A nucleoprotein was 12 
used as a model system. Exploiting the platform’s unique features, various typical bioassay parameters 13 
(e.g. aspecific binding between assay components, different reagent concentrations and incubation 14 
times) were tested for three capture antibodies in a simple and fast manner (2 runs of 80 min). The 15 
selected conditions, giving the highest signal-to-noise ratio, were directly employed on the same 16 
platform to detect nucleoprotein in buffer and nasopharyngeal swabs. Two antibodies with a higher 17 
dissociation constant (Ab11 and Ab12) required longer incubation times (60 min) for sensitive 18 
detection (limit of detection (LOD) of 0.48 and 0.26 ng mL-1, respectively) compared to an antibody 19 
with lower dissociation constant (LOD of 0.04 ng mL-1 for Ab66 within 30 min). Moreover, one antibody 20 
(Ab12) showed limited capacity to capture nucleoprotein directly in sample matrix. The obtained 21 
results were in accordance with previous studies performed on an ELISA and SPR platform with the 22 
same antibodies. This positions the EvalutionTM platform as a reliable platform for fast and multiplex 23 
analysis of antibodies’ performance both in buffer and complex sample matrices. 24 
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1. Introduction 28 
Bioassay development is one of the most crucial aspects for obtaining a functional biosensor and 29 
requires a methodological approach to select the ultimate assay components and conditions. 30 
Specifically, the bioreceptors have a major influence on the final assay performance since they 31 
determine not only the kinetics of the binding reaction but also the sensitivity and specificity of the 32 
interaction. Moreover, their performance in complex sample matrices defines the applicability of the 33 
developed bioassay in real samples. Ideally, receptors should bind to the target with fast kinetics, while 34 
discriminating it from other abundantly present sample components. To achieve this, multiple 35 
bioreceptors need to be tested for their interaction with the target under different conditions in order 36 
to select the most prominent candidate for the assay. 37 
Different techniques are available for the analysis of bioreceptor-target interactions, with enzyme-38 
linked immunosorbent assay (ELISA) and surface plasmon resonance (SPR)[1,2] being most commonly 39 
used. In a typical ELISA, the target is sandwiched between two antibodies and an enzyme is used to 40 
generate signal[3]. Although simple in its format while providing high throughput, standard ELISAs 41 
require significant handling time, have long time-to-result (because the different incubation times are 42 
largely dependent on diffusion), have high sample consumption and provide only endpoint 43 
measurements[1]. SPR is an alternative label-free technique used to monitor interactions of molecules 44 
(e.g. protein-protein, DNA-protein). Although it allows real time analysis in a short assay time, standard 45 
commercial SPR devices (e.g. Biacore) still have a low throughput, due to the limited number of flow 46 
channels, and low multiplexing capacity. Moreover, the measurements usually have a large reagent 47 
consumption, thereby increasing the assay cost and requiring a larger sample volume[2].  48 
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During the last couple of years, several methods have been developed to overcome the above 49 
mentioned disadvantages of the standard ELISA and SPR platforms. Thus, the size of bulky prism-based 50 
SPR instruments has been reduced, resulting in less sample consumption and decreased equipment 51 
and analysis cost. However, this comes at a price since the sensitivity of these systems is generally 52 
lower compared to the standard SPR systems[4–7]. Other techniques providing bioreceptor-target 53 
interaction analysis, such as dynamic force spectroscopy and microscale thermophoresis, consume 54 
limited amount of sample and allow single molecule analysis but have a very low throughput[8,9]. 55 
Recently, significant effort has been invested in developing platforms with high multiplexing capacity 56 
since it has a major influence on the total assay time and cost of the analysis system[3]. One of the 57 
most commonly used is the xMAP technology of Luminex. Here, magnetic beads are color coded with 58 
specific fluorophores and coated with antibodies to capture the target, which leads to signal 59 
generation that can be detected using flow cytometry or CCD imaging. Multiple sandwich 60 
immunoassay kits using the xMAP technology are commercially available[10]. Another possibility is 61 
printing multiple antibodies on specific spots on an antibody array and analyzing the interaction of 62 
each target with their corresponding spot (e.g. RayBiotech, Quansys Biosciences)[11,12]. Although 63 
these techniques allow high multiplex analysis, they still require significant hands-on time. To reduce 64 
the handling time and sample consumption, some microfluidic platforms have been successfully 65 
integrated with standard ELISA but have only limited multiplexing[13,14].  66 
Recently, a new platform called EvalutionTM (MyCartis NV, Belgium) has been launched that uses 67 
barcoded microparticles (µPs) in a fully automated microfluidic environment. While this platform 68 
combines fast assay time with a high level of multiplexing (up to 150-plex in one channel and the 69 
possibility to run up to 16 channels simultaneously), it also reduces sample consumption because the 70 
flow in the channels is generated by a pressure difference, thus avoiding the use of tubing. The 71 
instrument provides dynamic control over assay conditions by allowing real-time data processing and 72 
display. Because of all these features, EvalutionTM has the potential to be used not only for bioassay 73 
development but also for target detection. Although the standard ELISA and SPR systems can also be 74 
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used as diagnostic tools[15–18], the ongoing trends in the diagnostic field towards point-of-care tests 75 
and personalized medicine reduce their usability in those fields[19]. The first example showing the 76 
capacity of the EvalutionTM platform as a diagnostic tool was the sensitive detection of cytokines in a 77 
9-plex format[20]. 78 
In this work, the EvalutionTM platform has been evaluated for its potential for developing sandwich-79 
based assays in a fast and high-throughput fashion both in buffer as well as in complex sample matrix. 80 
A sandwich immunoassay for the detection of influenza A nucleoprotein is used as a model system. 81 
Previously, our group has used the same model on ELISA and SPR platforms[21] and hence these results 82 
can be used to benchmark the results obtained on EvalutionTM. Using the possibility to test multiple 83 
parameters in a single run, several analyses were performed to: (i) monitor the aspecific interaction 84 
between assay components and increase the signal-to-noise ratio, which is crucial in bioassay 85 
optimization; (ii) test the effect of varying incubation times of the nucleoprotein and (iii) test the assay 86 
performance using a complex sample matrix, namely nasopharyngeal swabs.  87 
2. Material and methods 88 
2.1. Reagents 89 
All reagents were purchased from Sigma-Aldrich (Belgium) unless stated otherwise. Based on 90 
previously published work[21], three commercially available monoclonal mouse antibodies 91 
(ab110661, ab128193 and ab66191) were selected for analyzing their binding affinity towards 92 
recombinant influenza A nucleoprotein, in this manuscript referred to as Ab11, Ab12 and Ab66, 93 
respectively. All monoclonal antibodies were raised against nucleoprotein isolated from real virus and 94 
purchased from Abcam plc. (United Kingdom). Polyclonal rabbit antibody against nucleoprotein 95 
(11675-RP01, referred to as secondary antibody) was purchased from SinoBiological Inc. (China). 96 
Biotinylated goat-anti-rabbit antibody (A16114, referred to as detection antibody) was obtained from 97 
Thermo Fisher Scientific Inc. (United States). Streptavidin labeled with phycoerythrin (SAPE-001, 98 
referred to as SA-PE) and buffer diluent (PECD-100) were purchased from Moss Inc. (United States). 99 
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LowCross buffer (100 500) was obtained from Candor Bioscience GmbH (Germany). Custom made 100 
recombinant influenza A nucleoprotein (IMR-274) was purchased from Imgenex (United States).  101 
2.2. EvalutionTM instrument 102 
The EvalutionTM platform relies on three major components, being barcoded µPs, microfluidic assay 103 
cartridges and an instrument for the integration of all assay steps[20]. The µPs are silicon discs with a 104 
diameter of 40 µm and a thickness of 10 µm. They are barcoded with 10 binary coding bits on their 105 
periphery, enabling 1024 (210) different codes. The central area is functionalized to allow coupling of 106 
biomolecules and is dedicated to measure fluorescence intensity. By the immobilization of different 107 
capture molecules onto differently encoded µPs, mixed µP populations can be prepared, creating a 108 
multiplex environment. These µPs are loaded into a microfluidic cartridge consisting of 16 microfluidic 109 
channels. Once the cartridge is inserted into the instrument, liquid transport is achieved by applying a 110 
pressure difference between the inlet and outlet of the microchannels (a more detailed description of 111 
this technology can be found in Falconnet et al., 2015[20]). Prior to each run, all channels are scanned 112 
to determine the background fluorescence signal. After capturing the analyte on the µP surface, a 113 
detection partner (either antibody or aptamer) labeled with a fluorophore is bound. Finally, the 114 
channels are scanned optically to identify the barcode of each µP and measure its corresponding 115 
fluorescence. All assay steps (incubation, washing, detection) are performed within the instrument. 116 
Moreover, it exhibits a temperature control between 25 °C and 95 °C, allowing also DNA hybridization 117 
analysis. 118 
2.3. Functionalization of microparticles 119 
The lyophilized µPs (MyCartis NV, Belgium) were resuspended in 200 µL molecular biology grade water. 120 
The liquid was immediately aspirated and transferred to an Eppendorf Protein LoBind tube containing 121 
100 µL activation solution (100 mM MES, 0.3 % Tween 20, pH 3.5). Any remaining µPs were transferred 122 
following the same procedure. Next, the µPs were washed three times with 500 µL activation solution. 123 
Next, the carboxylated µPs were activated using EDC/NHS chemistry. Briefly, a volume of 600 µL 124 
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activation solution containing 38 mM sulfo-NHS and 43 mM EDC was added. The µPs were 125 
homogenized by vortexing shortly and placed on a rotator mixer for 1 h. After incubation, the µPs were 126 
washed three times with activation solution and three times with coupling solution (100 mM MES, 127 
0.3 % Tween 20, pH 5.4). Activated µPs were suspended in 520 µL coupling solution and 80 µL of 0.5 128 
mg mL-1 protein solution in PBS (either Ab11, Ab12 or Ab66) was added. The µPs were vortexed and 129 
incubated for 1 h on the rotator mixer. Finally, the µPs were washed three times in storage buffer (10 130 
mM PBS, 0.3 % Tween 20, pH 7.4) and resuspended in 500 µL of the same buffer. Aliquots, each 131 
containing 2500 µPs, were prepared in Protein LoBind tubes by adding 62.5 µl of the functionalized 132 
particles to 100 µL storage buffer and stored at -20 °C until further use. 133 
2.4. Loading of the microfluidic cartridge with the functionalized microparticles 134 
Loading was performed in a semi-automated fashion using a cartridge loading station that interfaces 135 
with the cartridge (MyCartis NV, Belgium)[20]. Ab11, Ab12 and Ab66 were coupled to different 136 
populations of µPs using the protocol described in section 2.3, each representing a distinct population. 137 
A µP mix was prepared by mixing together one aliquot (2500 µPs) of each population and non-138 
functionalized control µPs in storage buffer to a final concentration of 5000 µPs mL-1. The microfluidic 139 
cartridge was inserted into the loading station. Prior to the loading, the inlet wells were filled with 20 140 
µL ethanol and the channels were primed by flowing for 2 seconds to wet the channels. Next, the 141 
ethanol was replaced by 110 µL storage buffer and a second priming step was performed. Following, 142 
100 µL of the µP mix was loaded to each channel until reaching 1 mm of loading length, which 143 
corresponds to approximately 39 µPs per population. Finally, the solution in the inlet wells was 144 
replaced with 100 µL storage buffer before starting the assay run. 145 
2.5. Signal-to-noise ratio optimization 146 
Two optimization experiments were performed for the different assay steps involved in the detection 147 
of nucleoprotein. Initially, four controls were tested. In control 1, SA-PE solution, prepared in SA-PE 148 
diluent, was flowed over the coupled particles at a concentration of 3 µg mL-1 for 5 min. For control 2, 149 
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detection antibody was flowed for 20 min at a concentration of 5 µg mL-1, followed by SA-PE incubation 150 
for 5 min at 3 µg mL-1 to generate the signal. In control 3, secondary and detection antibody were 151 
flowed sequentially for 20 min at a concentration of 3 and 5 µg mL-1, respectively, followed by SA-PE 152 
incubation for 5 min at 3 µg mL-1. For control 4, nucleoprotein was diluted in LC buffer and flowed for 153 
30 min at a concentration of 10 ng mL-1, followed by incubation with detection antibody for 20 min at 154 
a concentration of 5 µg mL-1 and SA-PE for 5 min at 3 µg mL-1. All antibody solutions were diluted in 155 
LowCross (LC) buffer. In between the different incubation steps and at the end of the assay, a short 156 
washing step of 1 min in storage buffer was introduced. In the second part of the optimization, 157 
nucleoprotein was incubated with the µPs for 30 min at four different concentrations (0, 0.1, 1 and 10 158 
ng mL-1). Next, the secondary antibody was flowed for 20 min at 3 µg mL-1. Then, 1 and 5 µg mL-1 of 159 
detection antibody was flowed for 10 and 20 min in separate channels. Short washing steps were 160 
introduced in between all incubations and at the end of the assay. The µPs were visualized using both 161 
bright field and fluorescent imaging. The bright field images were used for decoding and the average 162 
fluorescence intensity for each population was calculated using the supplied software. All tests were 163 
performed at 300 mbar pressure difference between inlet and outlet wells, which corresponds to a 164 
flow rate of approximately 30 nL s-1 (i.e. 36 µL sample consumption per channel for 20 min incubation 165 
time)[20]. Visualization of the fluorophore was achieved using the green laser (excitation at 532 nm, 166 
laser power 60 mW, exposure time of 150 ms) and CMOS camera (10x objective) present on-board of 167 
the instrument. 168 
2.6. Nucleoprotein detection in buffer 169 
The interaction of the nucleoprotein with the antibody-functionalized µPs was analyzed using a 170 
sandwich assay. First, nucleoprotein with concentrations ranging between 0.026 ng mL-1 and 80 ng mL-171 
1 was flowed over the functionalized µPs for different incubation times (15, 30 and 60 min). After 172 
incubation, the particles were washed with storage buffer for 1 min. Next, secondary antibody was 173 
introduced for 20 min at a concentration of 3 µg mL-1, followed by a single short washing step. 174 
Subsequently, biotinylated detection antibody was flowed for 10 min at 1 µg mL-1. All incubation steps 175 
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were performed in LC buffer. After a washing step, SA-PE solution, prepared in SA-PE diluent, was 176 
added at a concentration of 3 µg mL-1 and flowed for 5 min.  177 
2.7. Nucleoprotein detection in nasopharyngeal swabs  178 
The same sandwich assay protocol as described in section 2.6 was followed for the detection of 179 
nucleoprotein in nasopharyngeal swab eluates (in this paper referred to as nasopharyngeal swabs). 180 
Nasopharyngeal swabs, obtained from healthy donors, were eluted in 3 mL of universal transport 181 
medium and diluted 10 times in LC buffer. This solution was spiked with nucleoprotein at three 182 
different concentrations (80, 16 and 3.2 ng mL-1) and incubated for 15 min.  183 
3. Results and discussion 184 
3.1. Signal-to-noise ratio optimization 185 
Target recognition typically requires multiple steps in a bioassay (e.g. sandwich assay), unless a label-186 
free detection method is used. With every new component that is being introduced in each step, the 187 
possibility of aspecific interaction between different components is increasing. Hence, it is of 188 
importance to optimize the combination of assay components in order to obtain a high signal-to-noise 189 
ratio and consequently, a low limit of detection (LOD). This is especially important when analyzing 190 
complex sample matrices.  191 
A sandwich assay for the detection of influenza A nucleoprotein was used as a model system to conduct 192 
this study on the EvalutionTM platform. Four different steps were required to generate the binding 193 
signal (Figure 1A): (1) nucleoprotein capture by the capture antibody, which was immobilized on the 194 
µP surface, sequential binding of (2) secondary antibody and (3) biotinylated detection antibody and 195 
(4) binding of SA-PE for signal generation. Cross-reactivity between the different assay components 196 
was studied by including four different controls. In control 1, SA-PE was incubated directly with the 197 
capture antibodies and the bare µP surface. In control 2, detection antibody was additionally 198 
introduced compared to control 1. All assay components except for the nucleoprotein were included 199 
in control 3, whereas in control 4, the secondary antibody was omitted. For all conditions, the signal 200 
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obtained for the three capture antibodies (Ab11, Ab12 and Ab66) was compared to the one of the non-201 
functionalized µPs (COOH) in a multiplex analysis. The results are shown in Figure 1, together with a 202 
schematic of the assay setup for the detection of nucleoprotein. 203 
Control 1 showed low signal for all three tested antibodies (1 a.u.), which was only slightly higher than 204 
the background signal from the µPs (0.5 a.u.), indicating negligible amount of aspecific interaction 205 
between the immobilized antibodies and the SA-PE. The signal obtained from control 2 clearly showed 206 
a high aspecific interaction between the detection antibody and the capture antibodies, whereas the 207 
introduction of the secondary antibody (control 3) and the nucleoprotein (control 4) had negligible 208 
contribution to the aspecific interaction. Furthermore, the signal of the non-functionalized µPs 209 
remained stable (1 a.u.) in all four controls, which proved that none of the assay components interacts 210 
with the µPs. This is an intrinsic advantage of the EvalutionTM platform for the use in bioassay 211 
optimization as well as for target detection. Overall, the results indicated that the detection antibody 212 
was the major cause of the aspecific interaction. The difference in aspecific binding with the different 213 
capture antibodies was also observed previously for this assay when optimization was performed for 214 
standard ELISA. Importantly, the described analysis on the EvalutionTM platform was finalized in 80 min 215 
(i.e. total assay time from target incubation until signal generation, washing time included), whereas 216 
the same experiments required a total assay time of at least 250 min (washing time not included) when 217 
using ELISA[21]. The short assay time, together with significantly reduced reagent consumption due to 218 
the multiplexing capacity and the microfluidic environment, demonstrated the huge potential of using 219 
EvalutionTM for fast and straightforward bioassay optimization. 220 
In an attempt to reduce the aspecific interaction of the detection antibody with the capture antibodies 221 
and thus increase the signal-to-noise ratio, the incubation time and concentration of the detection 222 
antibody were decreased. A concentration of 1 µg mL-1 and 10 min incubation were tested and 223 
compared to the signal obtained for 20 min and 5 µg mL-1, which were used in the previous part. This 224 
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test was performed for four different nucleoprotein concentrations (0, 0.1, 1 and 10 ng mL-1). The 225 
results are shown in Figure 2. 226 
Using a high concentration of detection antibody (i.e. 5 µg mL-1, Figure 2A and B) gave higher specific 227 
signals compared to the lower concentration (i.e. 1 µg mL-1, Figure 2C and D). However, for the high 228 
concentration, also a higher aspecific signal (0 ng mL-1 of nucleoprotein) was observed as well as higher 229 
variation in the generated signal. The concentration had the biggest influence on the extend of 230 
aspecific interaction, while changing the incubation time was less effective in reducing the aspecific 231 
signal. Although a lower specific signal was obtained for the lower concentration, the signal-to-noise 232 
ratio was the highest for 1 µg mL-1 and 10 min incubation time (Figure 2D). Therefore, further 233 
experiments were performed using this condition. The flexibility of the EvalutionTM platform to control 234 
the flow for each channel separately allowed this experiment to be performed in one run with a total 235 
assay time of 75 min.  236 
3.2. Nucleoprotein detection in buffer 237 
The developed sandwich-based bioassay was used to detect six different concentrations of the 238 
nucleoprotein in buffer (ranging from 0.026 ng mL-1 to 80 ng mL-1) for 15, 30 and 60 min incubation 239 
time with the µPs. The obtained calibration curves are shown in Figure 3.  240 
The results revealed a time dependent increase in the signal for all antibodies with the longest 241 
incubation time (60 min) giving the highest signal. The effect of the incubation time was more 242 
pronounced for Ab11 than for Ab12 and Ab66. This difference can be explained by the dissociation 243 
constants (KD) of the antibodies. It was previously found that Ab11 had lower affinity towards the 244 
nucleoprotein (2.57 µM) compared to Ab12 (0.12 µM) and Ab66 (9.68 nM)[21], explaining the longer 245 
time that is needed to reach equilibrium. While for 15 min the behavior of the antibodies was very 246 
similar, for longer incubation times (30 and 60 min) there was a significant difference between the 247 
binding of Ab11 and the other two antibodies. Furthermore, Ab11 showed a better slope of the 248 
calibration curve (0.62) compared to the other two antibodies (0.26 for Ab12 and 0.40 for Ab66).  249 
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The LOD values have been calculated for each antibody, by interpolating from the linear calibration 250 
curves the concentration corresponding to a signal equal to three times the standard deviation of the 251 
mean background signal value. Table 1 summarizes the calculated LODs of all three capture antibodies 252 
for each condition. 253 
Although Ab11 showed the highest sensitivity, the calculated LOD of Ab12 and Ab66 was lower for all 254 
tested incubation conditions. It is clear that, when using Ab11, low concentrations of nucleoprotein 255 
can be detected only by extending the incubation time (60 min, LOD = 0.48 ng mL-1), whereas for Ab66 256 
30 min incubation was enough to reach a substantially lower LOD (0.04 ng mL-1). This can again be 257 
explained by the differences in KD values of the antibodies. As previously published work showed, Ab66 258 
has the lowest KD (9.68 nM) of all three antibodies and therefore could more efficiently bind to 259 
nucleoprotein compared to Ab11 and Ab12[21]. When these antibodies were previously tested in a 260 
standard ELISA, a similar LOD value was reached for Ab66 with 60 min interaction time (0.18 ng mL-1). 261 
However, a better LOD was obtained for both Ab11 and Ab12 (0.07 and 0.01 ng mL-1, respectively) 262 
compared to the EvalutionTM platform. In a standard ELISA, the influence of the diffusion of the analyte 263 
molecules on the interaction is not negligible (diffusion limited regime). Consequently, the KD of the 264 
antibodies has only limited influence on the binding. On the other hand, on the EvalutionTM platform, 265 
the target-receptor binding occurs in a reaction limited regime. This means the interaction depends 266 
purely on the affinity of the antibodies for their target and not on the supply of the analyte 267 
molecules[20]. Although the LOD for two antibodies was better in ELISA, the total assay time was at 268 
least 310 min (i.e. from target incubation until signal generation, washing steps not included), while 269 
the analysis performed on the EvalutionTM platform had a total assay time of only 100 min (washing 270 
steps included) and a reduced reagent consumption. For instance, for analyzing one sample in triplicate 271 
for its binding to three different antibodies within 15 min, 100 µL of sample was required on 272 
EvalutionTM compared to 900 µL on ELISA. This shows that the EvalutionTM platform is a valuable tool 273 
for the analysis of antibody performance and can serve as an alternative for standard ELISA and SPR 274 
experiments. Moreover, by reaching similar sensitivity as a standard ELISA, especially for antibodies 275 
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with low KD, the EvalutionTM platform holds huge potential to be used as a diagnostic platform because 276 
of its shorter assay time, reduced reagent consumption, multiplexing capacity and automation.  277 
3.3. Nucleoprotein detection in nasopharyngeal swabs 278 
Because target detection in clinical samples is crucial, the detection of nucleoprotein on the 279 
EvalutionTM platform was next tested in a relevant complex matrix. Several types of specimens are 280 
used in influenza diagnosis, such as swab, wash and aspirate originating from throat and nose. 281 
However, the most reliable detection is obtained using nasopharyngeal swabs[22]. In this study  282 
nasopharyngeal swabs obtained from healthy donors were diluted 10-fold to reduce aspecific 283 
binding[21]. The swabs were spiked with three different concentrations of recombinant nucleoprotein 284 
(3.2, 16 and 80 ng mL-1), similar to the assay performed in buffer. The assay configuration was identical 285 
to the previous experiments with 15 min of incubation for nucleoprotein. The difference in the 286 
antibody performance between LC buffer and nasopharyngeal swab is shown in Figure 4.  287 
While Ab12 showed a substantial decrease in binding in nasopharyngeal swabs, Ab11 and Ab66 were 288 
not influenced, suggesting they were more suited as bioreceptors for influenza A nucleoprotein 289 
detection. These results were also in accordance with previous findings on standard ELISA[21]. Ab11 290 
proved to be capable of capturing nucleoprotein directly in lysis buffer (0.1 % NLS), contrary to Ab12. 291 
Therefore, it can be concluded that the binding performance of Ab12 is strongly influenced by the 292 
sample matrix and it may only have limited use as capture antibody in clinical samples. Moreover, the 293 
obtained results demonstrated the capacity of the EvalutionTM platform to be used as a diagnostic 294 
system for target detection in a complex matrix.  295 
4. Conclusions 296 
In this work, the EvalutionTM platform has been evaluated as a tool for fast and straightforward 297 
bioassay optimization in buffer and complex sample matrix. A sandwich assay for the detection of 298 
influenza A nucleoprotein was used as a model system. To obtain a high signal-to-noise ratio and a low 299 
LOD, the aspecific interactions between six different components of the sandwich assay were first 300 
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tested. The high multiplexing capacity and possibility of running up to 16 channels simultaneously 301 
allowed four different controls and the complete bioassay to be executed in a single run (80 min) for 302 
three different capture antibodies. Moreover, the reagent consumption was reduced compared to a 303 
standard ELISA. The detection antibody caused significant aspecific signals due to interaction with the 304 
capture antibodies, as also previously observed on standard ELISA[21]. Hence, the highest signal-to-305 
noise ratio was obtained by lowering the concentration (from 5 to 1 µg mL-1) and incubation time (from 306 
20 to 10 min) of the detection antibody. Upon achieving the assay conditions giving the highest signal-307 
to-noise ratio, different concentrations of nucleoprotein were spiked in buffer and nasopharyngeal 308 
swabs for target detection using a fast (55 min) and automated assay. Although the obtained detection 309 
limits were varying for different antibodies and different assay time, they were overall comparable to 310 
a standard ELISA. The clear effect of the assay time on the LOD when using different capture antibodies 311 
can be explained by the fact that target-receptor binding occurs in a reaction limited regime on the 312 
EvalutionTM platform. Consequently, the interaction depends purely on the affinity of the antibodies 313 
for their target. The detection of nucleoprotein in nasopharyngeal swabs revealed the limited use of 314 
Ab12 as capture antibody for target detection directly in sample matrix. However, both Ab11 and Ab66 315 
showed stable binding behavior independently on the matrix used, which was in accordance with the 316 
previous study[21]. In conclusion, obtained results reveal the EvalutionTM platform as a valuable 317 
alternative for the well-established ELISA and SPR systems by allowing fast and multiplex analysis of 318 
antibody performance for bioassay optimization. Moreover, by reaching detection limits comparable 319 
to standard ELISA and allowing reliable detection in a complex sample matrix, this platform shows also 320 
huge potential to be further explored as a diagnostic tool for different application cases. Especially the 321 
short time-to-result and possibility of real-time analysis might be beneficial. Nevertheless, although up 322 
to 16 channels can be ran simultaneously, the throughput of the EvalutionTM platform is limited 323 
compared to the current gold standard analysis platforms, such as ELISA. However, for several 324 
applications, throughput might not be of major importance whereas time-efficient and cost-effective 325 
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batch testing can be crucial. Hence, the EvalutionTM platform might fulfill this need, especially with the 326 
recent trends in the diagnostic field showing a movement towards personalized diagnostics. 327 
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 392 
Figure 1: A) Assay layout for the detection of nucleoprotein (blue) with capture antibody (red) immobilized on the µP surface. 393 
Signal was generated by sequentially introducing a secondary antibody (yellow), biotinylated detection antibody (green) and 394 
SA-PE (brown). B) Aspecific interaction between the capture antibodies Ab11 (dark blue), Ab12 (light blue) and Ab66 (pink) 395 
and other assay components. Error bars are standard deviations of three repetitions. 396 
 397 
 398 
Figure 2: Comparison of the different incubation conditions for the detection antibody A) 5 µg mL-1 for 20 min, B) 5 µg mL-1 399 
for 10 min, C) 1 µg mL-1 for 20 min and D) 1 µg mL-1 for 10 min. Nucleoprotein (0.1, 1 and 10 ng mL-1) was incubated for 400 
30 min. The results are shown for Ab11 (dark blue), Ab12 (light blue) and Ab66 (pink). Error bars are standard deviation of 401 
the average signal obtained for all µPs per antibody population. 402 
 403 
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 404 
Figure 3: Calibration curves of nucleoprotein detection in LC buffer for A) 15 min, B) 30 min and C) 60 min incubation time 405 
with the capture antibodies (Ab11 (dark blue), Ab12 (light blue) and Ab66 (pink)). Five-fold dilutions of the nucleoprotein 406 
were tested, starting from 80 ng/mL, of which the linear part (0.026 ng mL-1 to 16 ng mL-1, i.e. five different concentrations) 407 
is shown here. The fluorescent signal was corrected for the background signal of the respective antibodies (i.e. 8.54 ± 1.17 408 
for Ab11, 1.92 ± 0.12 for Ab12 and 0.75 ± 0.95 for Ab66). Error bars are standard deviation of three repetitions. 409 
 410 
 411 
Figure 4: Nucleoprotein detection in nasopharyngeal swabs (light blue bar) and LC buffer (dark blue bar) for A) Ab11, B) Ab12 412 
and C) Ab66. Swabs of healthy people were diluted 10 fold in LC buffer and spiked with different concentrations of 413 
recombinant nucleoprotein (80, 16 and 3.2 ng mL-1). Incubation time for nucleoprotein was 15 min. Error bars are standard 414 
deviations of three repetitions.  415 
 416 
Table 1: Limit of detection (ng mL-1) for the capture of nucleoprotein with different assay conditions. 417 
 Nucleoprotein incubation time 
Antibody 15 min 30 min 60 min 
Ab11 3.04 ± 0.08 2.14 ± 0.10 0.48 ± 0.01 
Ab12 0.76 ± 0.04 0.38 ± 0.09 0.26 ± 0.09 
Ab66 0.60 ± 0.06 0.04 ± 0.02 0.19 ± 0.07 
 418 
